Skip to main content

Filana Therapeutics, Inc.

FLNA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001069530

In the last 90 days, Filana Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 78 institutions reported holding it in 13F filings for Q3 2026, worth $8.54M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 18, 2026
$27.4M
Insider buysLast 90 days, $356.3K in total
2
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, −5 vs. previous quarter
78
13F valueReported value at the end of Q3 2026
$8.54M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$91.0M
No comparable prior period
Free cash flow, FY2025
-$32.8M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
5.68M
Shares sold short
Change
+76.5K
+1.4% vs. previous
Days to cover
20.60
At average daily volume

Superinvestors holding FLNA, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding FLNA at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Filana Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 1, 2026 (view filing)7:57 AM ETSep 29-302 daysBarry RichardPresident & CEOPPurchase+306.8K$0.9065+$278.1K+29.8%1.34M after2 lots
Sep 30, 2026 (view filing)4:03 PM ETSep 282 daysBarry RichardPresident & CEOPPurchase+93.1K$0.84+$78.2K+9.9%1.03M after
Nov 25, 2025 (view filing)Nov 241 dayAnderson Robert Eugene JrDirectorPPurchase+8.60K$2.90+$24.9KNew position8.60K after
Nov 24, 2025 (view filing)Nov 204 daysBarry RichardPresident & CEOPPurchase+150.0K$2.76+$414.0K+19.0%938.1K after
Nov 20, 2025 (view filing)Nov 191 dayBarry RichardPresident & CEOPPurchase+73.4K$2.75+$201.8K+10.3%788.1K after
Oct 2, 2025 (view filing)Sep 302 daysCook Robert ChristopherChief Operating & Legal OfficePPurchase+13.7K$2.91+$39.9KNew position13.7K after
Sep 23, 2025 (view filing)Sep 221 dayBarry RichardPresident & CEOPPurchase+7.17K$2.28+$16.4K+1.0%714.7K after
Sep 22, 2025 (view filing)Sep 18-194 daysBarry RichardPresident & CEOPPurchase+237.9K$2.25+$534.7K+50.7%707.5K after4 lots
Dec 3, 2024 (view filing)Nov 294 daysKupiec James WilliamChief Medical OfficerSSale−4.00K$3.87−$15.5K−100.0%0 after
Dec 3, 2024 (view filing)Nov 294 daysSchoen EricChief Financial OfficerSSale−2.00K$3.82−$7.64K−100.0%0 after

Top 10 13F holders, Q3 2026

See all 78 holders

The largest institutional positions in Filana Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding FLNA in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Capital Management LLC1,929,726$1.71M0.00%−45,255−2.3%Reduced
BlackRock, Inc.1,446,715$1.28M0.00%−6,846−0.5%Reduced
Marshall Wace, LLP1,161,405$1.03M0.00%−436,143−27.3%Reduced
Geode Capital Management, LLC612,195$542.6K0.00%−3,315−0.5%Reduced
GMT Capital Corp450,100$398.8K0.02%00.0%Unchanged
Gsa Capital Partners LLP435,661$386.0K0.02%+166,251+61.7%Added
Two Sigma Investments, LP423,400$375.1K0.00%−1,287,958−75.3%Reduced
Squarepoint Ops LLC375,992$333.1K0.00%+57,612+18.1%Added
Acadian Asset Management LLC317,177$280.0K0.00%+22,118+7.5%Added
Vanguard Fiduciary Trust Co315,889$279.9K0.00%00.0%Unchanged

1 member of Congress reported 5 trades in Filana Therapeutics, Inc. since 2020. Newest filings:

  1. Chris Jacobs

    House · NY · Jan 20, 2023

    Buy$1K-$15K

  2. Chris Jacobs

    House · NY · Dec 12, 2022

    Sell$1K-$15K

  3. Chris Jacobs

    House · NY · Nov 16, 2022

    Buy$1K-$15K

  4. Chris Jacobs

    House · NY · Sep 9, 2022

    Sell$1K-$15K

  5. Chris Jacobs

    House · NY · Jul 28, 2022

    Buy$15K-$50K